A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
- 22 October 2002
- journal article
- clinical trial
- Published by Wiley in Journal of Experimental Therapeutics and Oncology
- Vol. 2 (6) , 325-332
- https://doi.org/10.1046/j.1359-4117.2002.01039.x
Abstract
Depsipeptide (FR901228) is a bicyclic peptide isolated from Chromobacterium violaceum that has demonstrated potent in vitro cytotoxic activity against human tumor cell lines and in vivo efficacy agai...Keywords
This publication has 8 references indexed in Scilit:
- A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokineticsJournal of Pharmaceutical and Biomedical Analysis, 2000
- Depsipeptide (FR901228): A Novel Therapeutic Agent With Selective, In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia CellsBlood, 1999
- Determination of the antitumor agent depsipeptide in plasma by liquid chromatography on serial octadecyl stationary phasesJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expressionOncogene, 1998
- Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cellsBreast Cancer Research and Treatment, 1998
- FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase InhibitorExperimental Cell Research, 1998
- Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 CellsBioscience, Biotechnology, and Biochemistry, 1994
- FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.The Journal of Antibiotics, 1994